Amneal Pharmaceuticals (AMRX) Invested Capital (2017 - 2026)

Amneal Pharmaceuticals' Invested Capital history runs 10 years deep, the most recent figure standing at $2.5 billion for Q1 2026.

• In Q1 2026, Invested Capital rose 23.01% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $2.5 billion (up 23.01% YoY), while the FY2025 annual figure was $2.5 billion, up 5161.69% from the prior year.
• Invested Capital was $2.5 billion for Q1 2026 at Amneal Pharmaceuticals, up from $2.5 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $2.8 billion in Q3 2022 to a low of -$49.4 million in Q4 2024.
• Historically, Invested Capital has averaged $2.1 billion across 5 years, with a median of $2.4 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Invested Capital sank 102.02% in 2024, then soared 5161.69% in 2025.
• A 5-year view of Invested Capital shows it stood at $248.2 million in 2022, then surged by 882.99% to $2.4 billion in 2023, then tumbled by 102.02% to -$49.4 million in 2024, then jumped by 5161.69% to $2.5 billion in 2025, then rose by 1.01% to $2.5 billion in 2026.
• The last three Invested Capital figures came in at $2.5 billion (Q1 2026), $2.5 billion (Q4 2025), and $2.5 billion (Q3 2025), per Business Quant data.